FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TRMU-ST13

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TRMU-ST13
FusionPDB ID: 94319
FusionGDB2.0 ID: 94319
HgeneTgene
Gene symbol

TRMU

ST13

Gene ID

55687

6767

Gene nametRNA 5-methylaminomethyl-2-thiouridylate methyltransferaseST13 Hsp70 interacting protein
SynonymsLCAL3|MTO2|MTU1|TRMT|TRMT1AAG2|FAM10A1|FAM10A4|HIP|HOP|HSPABP|HSPABP1|P48|PRO0786|SNC6
Cytomap

22q13.31

22q13.2

Type of geneprotein-codingprotein-coding
Descriptionmitochondrial tRNA-specific 2-thiouridylase 1MTO2 homologlung cancer associated lncRNA 3mitochondrial 5-methylaminomethyl-2-thiouridylate-methyltransferasehsc70-interacting proteinHsp70-interacting proteinaging-associated protein 2heat shock 70kD protein binding proteinprogesterone receptor-associated p48 proteinputative tumor suppressor ST13renal carcinoma antigen NY-REN-33suppression of tumorigenic
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000424260, ENST00000290846, 
ENST00000381019, ENST00000476901, 
ENST00000216218, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score11 X 8 X 10=8809 X 8 X 6=432
# samples 1613
** MAII scorelog2(16/880*10)=-2.4594316186373
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(13/432*10)=-1.73251968913501
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TRMU [Title/Abstract] AND ST13 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TRMU [Title/Abstract] AND ST13 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TRMU(46748227)-ST13(41231891), # samples:2
TRMU(46749764)-ST13(41231891), # samples:2
Anticipated loss of major functional domain due to fusion event.TRMU-ST13 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TRMU-ST13 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TRMU-ST13 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TRMU-ST13 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TRMU-ST13 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
TRMU-ST13 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:46748227/chr22:41231891)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TRMU (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ST13 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000290846TRMUchr2246748227+ENST00000216218ST13chr2241231891-384311123101839509
ENST00000381019TRMUchr2246748227+ENST00000216218ST13chr2241231891-352379251519504
ENST00000290846TRMUchr2246742441+ENST00000216218ST13chr2241231891-35498183101545411
ENST00000381019TRMUchr2246742441+ENST00000216218ST13chr2241231891-322949851225406
ENST00000424260TRMUchr2246742441+ENST00000216218ST13chr2241231891-33125812081308366

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000290846ENST00000216218TRMUchr2246748227+ST13chr2241231891-0.0001359090.9998641
ENST00000381019ENST00000216218TRMUchr2246748227+ST13chr2241231891-0.0001206030.99987936
ENST00000290846ENST00000216218TRMUchr2246742441+ST13chr2241231891-0.0001108210.99988914
ENST00000381019ENST00000216218TRMUchr2246742441+ST13chr2241231891-9.82E-050.9999018
ENST00000424260ENST00000216218TRMUchr2246742441+ST13chr2241231891-0.000125770.99987423

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TRMU-ST13

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TRMUchr2246742441ST13chr2241231891498164PEGLFRNRFEVRNGELQKAIDLFTDA
TRMUchr2246742441ST13chr2241231891581124PEGLFRNRFEVRNGELQKAIDLFTDA
TRMUchr2246742441ST13chr2241231891818169PEGLFRNRFEVRNGELQKAIDLFTDA
TRMUchr2246748227ST13chr22412318911112267ISIEDNKVLGTHKGELQKAIDLFTDA
TRMUchr2246748227ST13chr2241231891792262ISIEDNKVLGTHKGELQKAIDLFTDA

Top

Potential FusionNeoAntigen Information of TRMU-ST13 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TRMU-ST13_46742441_41231891.msa
TRMU-ST13_46748227_41231891.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TRMU-ST13chr2246742441chr2241231891818HLA-B27:04NRFEVRNGEL0.99960.6359616
TRMU-ST13chr2246742441chr2241231891818HLA-B39:01NRFEVRNGEL0.9970.7185616
TRMU-ST13chr2246742441chr2241231891818HLA-B39:06NRFEVRNGEL0.99490.5233616
TRMU-ST13chr2246742441chr2241231891818HLA-A30:08RFEVRNGELQK0.98480.5952718
TRMU-ST13chr2246742441chr2241231891818HLA-B73:01VRNGELQKA0.99230.83281019
TRMU-ST13chr2246742441chr2241231891818HLA-C04:10RFEVRNGEL0.96940.6762716
TRMU-ST13chr2246742441chr2241231891818HLA-C04:07RFEVRNGEL0.96560.6823716
TRMU-ST13chr2246742441chr2241231891818HLA-B73:01NRFEVRNGE0.88340.5124615
TRMU-ST13chr2246742441chr2241231891818HLA-B39:12NRFEVRNGEL0.99610.7382616
TRMU-ST13chr2246742441chr2241231891818HLA-B73:01NRFEVRNGEL0.98520.5319616
TRMU-ST13chr2246742441chr2241231891818HLA-B14:03NRFEVRNGEL0.96470.5876616
TRMU-ST13chr2246742441chr2241231891818HLA-C18:01RFEVRNGEL0.9770.6791716
TRMU-ST13chr2246742441chr2241231891818HLA-C04:01RFEVRNGEL0.96560.6823716
TRMU-ST13chr2246742441chr2241231891818HLA-B27:09NRFEVRNGEL0.99960.8523616
TRMU-ST13chr2246742441chr2241231891818HLA-B27:08NRFEVRNGEL0.99950.7032616
TRMU-ST13chr2246742441chr2241231891818HLA-B27:06NRFEVRNGEL0.99950.6098616
TRMU-ST13chr2246742441chr2241231891818HLA-B39:31NRFEVRNGEL0.99710.7335616
TRMU-ST13chr2246742441chr2241231891818HLA-C07:22NRFEVRNGEL0.99120.5598616
TRMU-ST13chr2246742441chr2241231891818HLA-A30:01RFEVRNGELQK0.98770.6984718
TRMU-ST13chr2246748227chr22412318911112HLA-B39:06THKGELQKA0.99260.78361019
TRMU-ST13chr2246748227chr22412318911112HLA-A30:08GTHKGELQK0.99250.5809918
TRMU-ST13chr2246748227chr22412318911112HLA-B15:10THKGELQKA0.70290.55641019
TRMU-ST13chr2246748227chr22412318911112HLA-B15:37THKGELQKA0.43680.63791019
TRMU-ST13chr2246748227chr22412318911112HLA-A30:01GTHKGELQK0.99130.7732918
TRMU-ST13chr2246748227chr22412318911112HLA-B15:09THKGELQKA0.69520.91791019

Top

Potential FusionNeoAntigen Information of TRMU-ST13 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TRMU-ST13_46742441_41231891.msa
TRMU-ST13_46748227_41231891.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TRMU-ST13chr2246742441chr2241231891818DRB1-1367RNRFEVRNGELQKAI520
TRMU-ST13chr2246742441chr2241231891818DRB1-1367FRNRFEVRNGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1117DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1117EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1152DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1152EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1189DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1189EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1354DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1377DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1401DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1401EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1401IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1404DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1404EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1404IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1405DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1405EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1407DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1407EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1408DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1408EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1411DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1411EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1416DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1418DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1418EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1423DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1423EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1426DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1426EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1426IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1428DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1428EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1431DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1432DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1432EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1435DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1435EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1435IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1435NKVLGTHKGELQKAI520
TRMU-ST13chr2246748227chr22412318911112DRB1-1438DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1438EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1439DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1439EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1443DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1443EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1445DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1445EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1450DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1450EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1454DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1454EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1454IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1455DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1455EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1456DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1456EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1458DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1458EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1458IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1459DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1459EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1460DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1460EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1460IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1461DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1461EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1461IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1462DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1462EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1462IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1464DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1464EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1465DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1468DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1470DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1470EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1471DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1471EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1471IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1472DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1472EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1473DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1473EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1474DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1475DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1475EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1475IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1482DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1482EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1486DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1486EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1486IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1487DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1487EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1487IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1488DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1488EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1488IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1490DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1490EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1490IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1491DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1491EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1495DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1495EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1496DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1496EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1497DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1497EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1497IEDNKVLGTHKGELQ217
TRMU-ST13chr2246748227chr22412318911112DRB1-1499DNKVLGTHKGELQKA419
TRMU-ST13chr2246748227chr22412318911112DRB1-1499EDNKVLGTHKGELQK318
TRMU-ST13chr2246748227chr22412318911112DRB1-1499IEDNKVLGTHKGELQ217

Top

Fusion breakpoint peptide structures of TRMU-ST13

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4679KVLGTHKGELQKAITRMUST13chr2246748227chr22412318911112
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6349NRFEVRNGELQKAITRMUST13chr2246742441chr2241231891818

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TRMU-ST13

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4679KVLGTHKGELQKAI-7.15543-7.26883
HLA-B14:023BVN4679KVLGTHKGELQKAI-4.77435-5.80965
HLA-B52:013W394679KVLGTHKGELQKAI-6.80875-6.92215
HLA-B52:013W394679KVLGTHKGELQKAI-4.20386-5.23916
HLA-A11:014UQ24679KVLGTHKGELQKAI-7.5194-8.5547
HLA-A11:014UQ24679KVLGTHKGELQKAI-6.9601-7.0735
HLA-A24:025HGA4679KVLGTHKGELQKAI-7.52403-7.63743
HLA-A24:025HGA4679KVLGTHKGELQKAI-5.82433-6.85963
HLA-B27:056PYJ4679KVLGTHKGELQKAI-3.28285-4.31815
HLA-B44:053DX84679KVLGTHKGELQKAI-5.91172-6.94702
HLA-B44:053DX84679KVLGTHKGELQKAI-4.24346-4.35686
HLA-B14:023BVN6349NRFEVRNGELQKAI-7.9962-8.1096
HLA-B14:023BVN6349NRFEVRNGELQKAI-5.70842-6.74372
HLA-B52:013W396349NRFEVRNGELQKAI-6.83737-6.95077
HLA-B52:013W396349NRFEVRNGELQKAI-4.4836-5.5189
HLA-A11:014UQ26349NRFEVRNGELQKAI-10.0067-10.1201
HLA-A11:014UQ26349NRFEVRNGELQKAI-9.03915-10.0745
HLA-A24:025HGA6349NRFEVRNGELQKAI-6.56204-6.67544
HLA-A24:025HGA6349NRFEVRNGELQKAI-5.42271-6.45801
HLA-B44:053DX86349NRFEVRNGELQKAI-7.85648-8.89178
HLA-B44:053DX86349NRFEVRNGELQKAI-5.3978-5.5112
HLA-A02:016TDR6349NRFEVRNGELQKAI-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of TRMU-ST13

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TRMU-ST13chr2246742441chr22412318911019VRNGELQKATTAGAAATGGTGAACTCCAGAAAGCCA
TRMU-ST13chr2246742441chr2241231891615NRFEVRNGEATCGGTTTGAAGTTAGAAATGGTGAAC
TRMU-ST13chr2246742441chr2241231891616NRFEVRNGELATCGGTTTGAAGTTAGAAATGGTGAACTCC
TRMU-ST13chr2246742441chr2241231891716RFEVRNGELGGTTTGAAGTTAGAAATGGTGAACTCC
TRMU-ST13chr2246742441chr2241231891718RFEVRNGELQKGGTTTGAAGTTAGAAATGGTGAACTCCAGAAAG
TRMU-ST13chr2246748227chr22412318911019THKGELQKACACATAAAGGTGAACTCCAGAAAGCCA
TRMU-ST13chr2246748227chr2241231891918GTHKGELQKGAACACATAAAGGTGAACTCCAGAAAG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
TRMU-ST13chr2246742441chr2241231891419FRNRFEVRNGELQKATCAGAAATCGGTTTGAAGTTAGAAATGGTGAACTCCAGAAAGCCA
TRMU-ST13chr2246742441chr2241231891520RNRFEVRNGELQKAIGAAATCGGTTTGAAGTTAGAAATGGTGAACTCCAGAAAGCCATTG
TRMU-ST13chr2246748227chr2241231891217IEDNKVLGTHKGELQTAGAAGACAATAAGGTTCTGGGAACACATAAAGGTGAACTCCAGA
TRMU-ST13chr2246748227chr2241231891318EDNKVLGTHKGELQKAAGACAATAAGGTTCTGGGAACACATAAAGGTGAACTCCAGAAAG
TRMU-ST13chr2246748227chr2241231891419DNKVLGTHKGELQKAACAATAAGGTTCTGGGAACACATAAAGGTGAACTCCAGAAAGCCA
TRMU-ST13chr2246748227chr2241231891520NKVLGTHKGELQKAIATAAGGTTCTGGGAACACATAAAGGTGAACTCCAGAAAGCCATTG

Top

Information of the samples that have these potential fusion neoantigens of TRMU-ST13

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SKCMTRMU-ST13chr2246742441ENST00000290846chr2241231891ENST00000216218TCGA-D3-A2JC-06A
SKCMTRMU-ST13chr2246748227ENST00000290846chr2241231891ENST00000216218TCGA-D3-A2JC-06A

Top

Potential target of CAR-T therapy development for TRMU-ST13

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TRMU-ST13

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TRMU-ST13

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource